Education

  • Iran University of Medical Sciences, MD, Medicine
  • Yale School of Public Health, MPH, Epidemiology and Biostatistics
  • Boston University Medical Center, Residency, Internal Medicine
  • Washington University School of Medicine, Fellowship, Hematology and Medical Oncology
  • Washington University School of Medicine, Certificate, Clinical Investigation

Honors & Awards

  • 2016 Society of Hematologic Oncology (SOHO) Travel Grant
  • 2016 Cancer Genomics Research Strength Scholar, Helen Diller Family Comprehensive Cancer Center, UCSF
  • 2020 Junior Faculty Development Award, Helen Diller Family Comprehensive Cancer Center, UCSF

Selected Publications

  1. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 11; 19(11):1218-1230.  View on PubMed
  2. Fakhri B, Ai W. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol. 2021; 12:20406207211048959.  View on PubMed
  3. Banerjee R, Fakhri B, Shah N. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leuk Lymphoma. 2021 11; 62(11):2600-2611.  View on PubMed
  4. Fakhri B, Yilmaz E, Gao F, Ambinder RF, Jones R, Bartlett NL, Cashen A, Wagner-Johnston N. Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. 2021 10; 62(10):2408-2415.  View on PubMed
  5. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.  View on PubMed
  6. Kennedy VE, Ruiz-Cordero R, Jangam D, Wen KW, Dunavin N, Ohgami RS, Bhargava P, Ai W, Fakhri B. A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e583-e587.  View on PubMed
  7. Fakhri B, Andreadis C. The role of acalabrutinib in adults with chronic lymphocytic leukemia. Ther Adv Hematol. 2021; 12:2040620721990553.  View on PubMed
  8. Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):139-146.  View on PubMed
  9. Parks AL, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong SW, Shah N, Fang MC. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leuk Lymphoma. 2021 04; 62(4):1003-1006.  View on PubMed
  10. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):246-256.e2.  View on PubMed
  11. Wen KW, Fakhri B, Menke J, Ruiz-Cordero R, Gill RM, Ohgami RS. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide. Ann Diagn Pathol. 2020 Jun; 46:151534.  View on PubMed
  12. Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020 07 15; 26(14):3589-3596.  View on PubMed
  13. Kambhampati S, Gray L, Fakhri B, Lo M, Vu K, Arora S, Kaplan L, Ai WZ, Andreadis C. Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series. Clin Lymphoma Myeloma Leuk. 2020 03; 20(3):e118-e123.  View on PubMed
  14. Fakhri B, Andreadis C. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL. Oncology (Williston Park). 2019 Nov 14; 33(11).  View on PubMed
  15. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer. 2020 02 15; 126(4):808-813.  View on PubMed
  16. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 01 15; 126(2):293-303.  View on PubMed
  17. Fakhri B, Cashen AF, Duncavage EJ, Watkins MP, Wartman LD, Bartlett NL. Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e532-e535.  View on PubMed
  18. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019 02; 184(4):524-535.  View on PubMed
  19. Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D. Bones in Multiple Myeloma: Imaging and Therapy. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:638-646.  View on PubMed
  20. Fakhri B, Fiala MA, Tuchman SA, Wildes TM. Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clin Lymphoma Myeloma Leuk. 2018 03; 18(3):219-224.  View on PubMed

Go to UCSF Profiles, powered by CTSI